Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 999302 add-on to REKOVELLE in controlled ovarian stimulation
2017-003810-13Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in female infertility, Tubal factor infertility (TFI) and Unexplained infertility comparing FE 999302 add-on to follitropin delta with Placebo add-on to follitropin delta (2 arms). Primary endpoint: Number of good-quality blastocysts on day 5 after oocyte retrieval. Started Apr 2018; status: completed.
02
Drugs
choriogonadotropin beta
03
Conditions
female infertilityTubal factor infertility (TFI)Unexplained infertility
Beyond the preview
Go deeper on 2017-003810-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003810-13.